Boston, Massachusetts, United States, September 2025 – Amgen, one of the world’s leading biotechnology companies, has announced the appointment of Sunil Mehta as Vice President, Global Medical Affairs TA Head, Rare Disease. In this pivotal leadership role, Mehta will spearhead Amgen’s global medical affairs strategy for rare diseases, ensuring alignment with the company’s mission To Serve Patients. His appointment also marks a return to Amgen, where he began his career journey in medical affairs almost two decades ago.
Most recently, Sunil served as Senior Vice President of Medical Affairs at Annexon Biosciences, where he directed medical strategy and engagement to advance therapies for patients across neuroscience and rare indications. His leadership was instrumental in strengthening Annexon’s medical affairs infrastructure and supporting key clinical milestones.
Prior to this, he was Vice President, Head of Medical Affairs at argenx, where over four years he successfully expanded medical affairs capabilities and developed medical engagement strategies supporting the company’s innovative rare disease portfolio.
Earlier, Sunil spent close to a decade at Alexion Pharmaceuticals, where he rose through multiple leadership roles. He served as Executive Director, US Neurology TA Medical Lead, preceded by roles as Senior Director of the Neurology MSL Team, Director of the US Complement MSL Team, and Regional Director for Hematology-Nephrology MSLs. His tenure included building high-performing field medical teams, leading advisory boards and congress strategies, and shaping medical engagement in ultra-rare disease markets. He began at Alexion as a Senior Medical Science Liaison, engaging extensively with KOLs and medical societies to strengthen scientific exchange and clinical collaboration.
Sunil’s earlier career includes an impactful tenure at Amgen as Senior Regional Medical Science Liaison, covering major territories across the United States. This experience laid the foundation for his return to the company in a senior global leadership role, reflecting both continuity and growth in his professional trajectory.
About Amgen
Amgen is a pioneer in the biotechnology industry, harnessing biology and technology to fight the world’s most challenging diseases and improve patient outcomes. With an extensive portfolio spanning oncology, cardiology, osteoporosis, inflammation, and rare diseases, Amgen continues to advance cutting-edge research supported by human genetic data and innovative technologies.
Recognized as one of the “World’s Most Innovative Companies” by Fast Company and one of “America’s Best Large Employers” by Forbes in 2024, Amgen is also part of the Dow Jones Industrial Average® and the Nasdaq-100 Index®. The company remains committed to pushing the boundaries of science to deliver transformative therapies for patients globally.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
